Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
CAS Registry Number
3522-50-7
Molecular formula
C6H5FeO7
Molecular weight
244.94 g/mol
Drug class
Ferric iron–citrate complexphosphate-binding agent and iron source
Mechanism of action
Ferric iron binds dietary phosphate in the gastrointestinal tract, forming insoluble ferric-phosphate complexes that are eliminated in the faeces. The complex can also provide absorbable iron; these functions are product- and formulation-specific.
Indications / reported uses
Control of serum phosphorus in adults with chronic kidney disease on dialysis
Treatment of iron-deficiency anaemia in adults with chronic kidney disease not on dialysis under the applicable product indication; monitor iron indices and phosphate
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Ferric Citrate Environmental Risk Assessment (ERA) (the Ferric Citrate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.